Orgaran (Danaparoid Sodium)

Danaparoid Sodium selectively inhibits factor Xa by enhancing the activity of antithrombin III and heparin cofactor II. This reduces thrombin generation, limiting fibrin clot formation while preserving platelet function, which provides effective anticoagulation.

The specific dose of Orgaran is determined by the prescribing clinician based on the patient’s condition, weight, renal function and the clinical setting. Healthcare professionals should follow institutional protocols and adjust dosing as needed.

Orgaran should be used in pregnancy only when clearly indicated and when the potential benefits outweigh the risks to the fetus. Limited data are available for breastfeeding, so caution is advised and a risk‑benefit assessment should be performed by the treating physician.

To order Orgaran, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Orgaran (Danaparoid Sodium) is distinct from unfractionated heparin and low‑molecular‑weight heparins because it has a lower risk of cross‑reactivity in heparin‑induced thrombocytopenia and provides a more predictable anti‑Xa activity. It is often chosen when HIT is present or when a stable anti‑Xa effect is required.

Orgaran should be stored at 2‑8°C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use and discard any solution that appears discolored or contains particles.

Orgaran is given intravenously under aseptic conditions. The infusion rate and duration are set by the prescribing clinician, typically using a calibrated infusion pump, and patients are monitored for anticoagulation parameters and signs of bleeding.

The most serious risks include major hemorrhage, thrombocytopenia, allergic anaphylactic reactions, disseminated intravascular coagulation and severe hypotension. Prompt recognition and management of these events are essential.

Orpatients who have a known hypersensitivity to Danaparoid Sodium or any component of the formulation, active uncontrolled bleeding, severe thrombocytopenia unrelated to HIT, or those for whom anticoagulation is contraindicated should not receive Orgaran.